TOVX ownership update: 739,211 shares disclosed on Schedule 13G
Rhea-AI Filing Summary
Theriva Biologics (TOVX) reported a new Schedule 13G indicating that the Jeffrey Matthew Gryga Irrevocable Trust beneficially owns 739,211 shares of common stock, representing 7.7% of the class as of the event date 10/24/2025.
The trust has sole voting and dispositive power over these 739,211 shares. Jeffrey Matthew Gryga, as sole trustee, reports shared voting and dispositive power over the same shares through the trust. The filing includes a certification that the securities were not acquired for the purpose of changing or influencing control of the issuer.
Positive
- None.
Negative
- None.
FAQ
What did the Schedule 13G disclose for TOVX?
The Jeffrey Matthew Gryga Irrevocable Trust reported beneficial ownership of 739,211 TOVX common shares, equal to 7.7% of the class.
What voting and dispositive powers were reported?
The trust has sole voting and dispositive power over 739,211 shares; Jeffrey Matthew Gryga reports shared power over the same shares as trustee.
What is the reported percentage ownership of TOVX?
The filing states a 7.7% beneficial ownership of the common stock class.
What is the event date for this ownership report?
The date of the event requiring the filing is 10/24/2025.
Did the filer indicate an intent to influence control of TOVX?
No. The certification states the securities were not acquired for the purpose of changing or influencing control.
Is this filing made as part of a group?
The filing does not identify a group and is presented by the trust and trustee together under a joint filing agreement.
AI-generated analysis. How Rhea-AI works. Not financial advice.